Tofacitinib as a treatment of alopecia areata in adolescents

• Published in: Boletin medico del Hospital Infantil de Mexico Vol. 76; no. 4; p. 182
• Main Authors: Morales-Miranda, Adalid Y, Bueno-Arias, Guadalupe M, Aguirre-Félix, Óscar G, Tovar-Franco, Rocío
• Format: Journal Article
• Language: English; Spanish
• Published: Mexico 2019
• Subjects: Administration, Oral; Adolescent; Alopecia Areata - drug therapy; Alopecia Areata - pathology; Female; Humans; Male; Mexico; Piperidines - administration & dosage; Protein Kinase Inhibitors - administration & dosage; Pyrimidines - administration & dosage; Pyrroles - administration & dosage; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult; Mexico; Tofacitinib; Janus kinases (JAK); Alopecia areata
• ISSN: 1665-1146
• DOI: 10.24875/BMHIM.19000005

Currently, no standardized treatment for severe alopecia areata (AA) exists. Numerous successful cases of the use of tofacitinib have been reported in the world literature, but not in Mexico. Four Mexican adolescents with severe AA treated with oral tofacitinib are reported in the present work. Series of cases of adolescents with severe AA treated with oral tofacitinib. The severity of alopecia tool was used to determine the response to treatment. Four patients from 13 to 19 years old, were included. In all cases, hair growth was observed, and the alopecia severity decreased after the treatment with tofacitinib. In two patients, an intermediate response (from 51 to 90%) was observed; in the other, a moderate response (from 6 to 50%) was observed, without serious adverse effects. The limitations of the study were the small sample size and the retrospective nature of data collection. Tofacitinib showed to be a good treatment alternative for AA, total and universal, refractory to other therapies.